Nonalcoholic Fatty Liver Disease: What's the Long-Term Prognosis?
Atif Zaman, MD, MPH
Obeticholic Acid Shows Promise for NAFLD and Type 2 Diabetes
Atif Zaman, MD, MPH
David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)
Do Steroid Injections Work for Esophagogastric Anastomotic Strictures?
David A. Johnson, MD
Surveillance of Nondysplastic Barrett Esophagus Is Not Supportable
David A. Johnson, MD
Interferon-Free Regimen for HCV Genotype 1 Infection: Closer Still
Atif Zaman, MD, MPH
Comparing Nonbismuth Quadruple Regimens for Helicobacter Pylori Eradication
David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)
Douglas K. Rex, MD
Probiotics May Alter Brain Activity Involving Emotional Regulation
Douglas K. Rex, MD
In a large population-based screening study, the OC Sensor (Polymedco) test was superior to the Magstream test.
Experts widely agree that a fecal immunochemical test (FIT) should replace a guaiac-based fecal occult blood test for colorectal cancer (CRC) screening because of its higher adherence rates and superior performance characteristics. However, the performance characteristics of different FITs have been shown to vary dramatically (Ann Intern Med 2009; 150:162). Therefore, the clinical issue has not been whether to use a FIT, but which FIT to use. In the current study, investigators compared the OC Sensor FIT (Eiken Chemical Co., Tokyo, Japan), commonly studied in clinical trials, to the Magstream FIT (Fujirebio, Inc., Tokyo, Japan), and the Hemoccult II guaiac test (SKD, Villepinte, France).
